Lipoprotein(a) Measurement in Clinical Practice

To the Editor With great interest we read the Teachable Moment by Furlan et al regarding the usefulness of lipoprotein(a) (Lp[a]) measurement in clinical practice. The authors describe a patient at very low risk of cardiovascular disease (CVD) with an Lp(a) concentration of 110 mg/dL, concluding that statin therapy should not be recommended in view of the low risk. The authors argue that Lp(a) is a biomarker of unknown clinical significance, in absence of either approved drugs lowering Lp(a) or randomized clinical trials showing that reduction in Lp(a) results in CVD risk reduction. We feel that these conclusions merit a wider perspective.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research